Enrollment for 2018 in Affordable Care Act plans is only slightly below figures from 2017; a rare breed of antibiotic-resistant bacteria is spreading in hospitals; a new company will develop off-the-shelf CAR T-cell therapies that do not need to be personalized to the patient.
The final figures for enrollment in Affordable Care Act insurance plans showed that 11.8 million signed up in 2018. According to The Washington Post, the numbers represent a slight dip of just 400,000 from 2017. Enrollment in states that operated their own marketplaces was flat, while enrollment dropped in the 39 states on the federal marketplace. The proportion of consumers qualifying for subsidies remained level at 83%, while first-time consumers dropped from 31% to 27% of all enrollees.
In 2017, there were more than 220 cases of a rare breed of bacteria that is mostly untreatable, and which has taken CDC by surprise. Up to half of infections caused by these superbugs are fatal, reported Kaiser Health News. In addition, 1 in 10 cases of people infected with the germs spread the disease to healthy people who act as silent carriers. The good news is that hospitals can limit the spread of outbreaks from these bacteria with aggressive measures, such as wearing gowns and gloves while caring for infected patients. Containing these infections can reduce them by 76%.
Chimeric antigen receptor (CAR) T-cell therapies need to be personalized to each patient, but a new company is looking to develop off-the-shelf therapies that do not need to be personalized. Allogene Therapeutics was launched Tuesday by 2 former executives of Kite Pharma and has bought Pfizer’s portfolio of cell therapies, according to STAT. The new approach would harvest and modify cells taken from a healthy donor to then use to treat any eligible patient with cancer. Currently, CAR T therapies are made by collecting cells from a patient with cancer, modifying them, and reinfusing the cells back into the patient. While current CAR T-cell therapies have been highly successful, it is time consuming to create them.
Data Back Neoadjuvant Combo vs Chemo Alone for Early-Stage NSCLC
April 24th 2024For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More